![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: ATP2B2 |
Gene summary for ATP2B2 |
![]() |
Gene information | Species | Human | Gene symbol | ATP2B2 | Gene ID | 491 |
Gene name | ATPase plasma membrane Ca2+ transporting 2 | |
Gene Alias | PMCA2 | |
Cytomap | 3p25.3 | |
Gene Type | protein-coding | GO ID | GO:0003008 | UniProtAcc | A0A024R2K6 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
491 | ATP2B2 | NAFLD1 | Human | Liver | NAFLD | 8.52e-14 | 8.99e-01 | -0.04 |
491 | ATP2B2 | S41 | Human | Liver | Cirrhotic | 1.22e-05 | 5.15e-01 | -0.0343 |
491 | ATP2B2 | HCC1_Meng | Human | Liver | HCC | 3.45e-53 | 7.70e-02 | 0.0246 |
491 | ATP2B2 | HCC2 | Human | Liver | HCC | 4.73e-04 | 2.03e+00 | 0.5341 |
491 | ATP2B2 | S027 | Human | Liver | HCC | 4.59e-02 | 4.67e-01 | 0.2446 |
491 | ATP2B2 | S028 | Human | Liver | HCC | 1.86e-05 | 3.15e-01 | 0.2503 |
491 | ATP2B2 | S029 | Human | Liver | HCC | 6.93e-12 | 6.52e-01 | 0.2581 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Liver | ![]() | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ATP2B2 | SNV | Missense_Mutation | novel | c.2896A>G | p.Ile966Val | p.I966V | Q01814 | protein_coding | tolerated(0.19) | benign(0.015) | TCGA-DD-AAEB-01 | Liver | liver hepatocellular carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
ATP2B2 | SNV | Missense_Mutation | rs202118324 | c.1576N>A | p.Asp526Asn | p.D526N | Q01814 | protein_coding | tolerated(0.31) | benign(0.003) | TCGA-DD-AAVR-01 | Liver | liver hepatocellular carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
ATP2B2 | SNV | Missense_Mutation | c.1801N>T | p.Thr601Ser | p.T601S | Q01814 | protein_coding | deleterious(0.02) | probably_damaging(0.946) | TCGA-G3-A7M6-01 | Liver | liver hepatocellular carcinoma | Female | <65 | I/II | Unknown | Unknown | PD | |
ATP2B2 | SNV | Missense_Mutation | c.2378N>T | p.Pro793Leu | p.P793L | Q01814 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-05-4382-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
ATP2B2 | SNV | Missense_Mutation | c.2453C>T | p.Thr818Met | p.T818M | Q01814 | protein_coding | deleterious(0.01) | probably_damaging(0.994) | TCGA-05-4417-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
ATP2B2 | SNV | Missense_Mutation | c.651N>C | p.Lys217Asn | p.K217N | Q01814 | protein_coding | deleterious(0.04) | possibly_damaging(0.516) | TCGA-44-A4SS-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
ATP2B2 | SNV | Missense_Mutation | c.1489T>A | p.Cys497Ser | p.C497S | Q01814 | protein_coding | deleterious(0.01) | possibly_damaging(0.903) | TCGA-53-7626-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Unspecific | Cisplatin | PD | |
ATP2B2 | SNV | Missense_Mutation | novel | c.3233N>T | p.Gly1078Val | p.G1078V | Q01814 | protein_coding | deleterious(0) | probably_damaging(0.978) | TCGA-55-7911-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
ATP2B2 | SNV | Missense_Mutation | c.2104G>T | p.Val702Leu | p.V702L | Q01814 | protein_coding | tolerated(0.1) | benign(0.218) | TCGA-55-8203-01 | Lung | lung adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
ATP2B2 | SNV | Missense_Mutation | rs370895383 | c.3374N>A | p.Arg1125Gln | p.R1125Q | Q01814 | protein_coding | deleterious(0.01) | possibly_damaging(0.827) | TCGA-55-8620-01 | Lung | lung adenocarcinoma | Male | <65 | III/IV | Unknown | Unknown | PD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |